Μια πρωτοβουλία της GSK

Βιβλιογραφία

  1. Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367(9508):397-403
  2. Meningococcal meningitis factsheet No 141. World Health Organization website. link . Updated November 2012. Accessed October 14, 2014.
  3. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009;27(Suppl 2):B51-63.
  4. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med. 2001;344(18):1378-1388.
  5. European Centre for Disease Prevention and Control (ECDC).Surveillance of invasive bacterial diseases in Europe, 2011. Stockholm, Sweden: ECDC; 2013.xs
  6. Ladhani SN, Flood JS, Ramsay ME, et al. Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines. Vaccine. 2012;30(24):3710-3716.
  7. Parent du Châtelet I, Taha MK, Lepoutre A, Maine C, Deghmane AE, Bruhl DL. Les infections invasives à méningocoques en France en 2011: principales caractéristiques épidémiologiques. Bull Épidémiol Hebd. 2012;49-50:569-573.
  8. Stephens DS.Conquering the meningococcus.FEMS Microbiol Rev. 2007;31(1):3-14.
  9. Harrison LH. Prospects for vaccine prevention of meningococcal infection. Clin Microbiol Rev.2006;19(1): 142-164.
  10. Li YA, Tsang R, Desai S, Deehan H. Enhanced surveillance of invasive meningococcal disease in Canada, 2006-2011. Can Commun Dis Rep.2014;40-9:160-169.
  11. European Centre for Disease Prevention and Control (ECDC).Surveillance of invasive bacterial diseases in Europe, 2011. Stockholm, Sweden: ECDC; 2013.
  12. Lahra MM, Enriquez RP. Australian Meningococcal Surveillance Programme Annual Report, 2012. Commun Dis Intell Q Rep.2013;37(3):E224-232.
  13. Organización Panamericana de la Salud.Informe Regional de SIREVA II, 2012: datos por país y por grupos de sobre las características de los aislamientos de Streptococcus pneumoniae, Haemophilus influenzae y Neisseria meningitidis, en procesos invasavores.Washington, DC: Organización Panamericana de la Salud; 2013;2013.
  14. Grupo de Microbiologia: Neisseria meningitidis (aislamientos invasores), 2012.Instituto Nacional de Salud website. Accessed October 15, 2014.
  15. Lopez L, Sherwood J. Surveillance report: The epidemiology of meningococcal disease in New Zealand, 2013. Wellington, New Zealand: Institute of Environmental Science and Research Ltd (ESR); 2014.
  16. Trotter CL, Gay NJ, Edmunds WJ. The natural history of meningococcal carriage and disease. Epidemiol. Infect. 134(3), 556–566 (2006).
  17. Εθνικό Κέντρο Αναφοράς Μηνιγγίτιδας, Απολογισμός Έργου 2015, σελ.22
  18. Ereth J. The global value of vaccination. Vaccine 2003; 21: 596-600
  19. World Health Organization, Estimates of disease burden and cost-effectiveness
  20. Εθνικό Πρόγραμμα Εμβολιασμών Παιδιών και Εφήβων 2017
  21. Tzanakaki, G., (2014).Diversity of Greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccine. [online] Available at: https://bmcmicrobiol.biomedcentral.com/articles/10.1186/1471-2180-14-111 [Accessed 29 Apr. 2014]